Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:02:44 EDT Sat 18 May 2024
Enter Symbol
or Name
USA
CA



Q:SWTX - SPRINGWORKS THERAPEUTICS INC - http://www.Southwall.Com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SWTX - Q0.127.44·50.560.144.84+0.070.2630.424,7196,28244.65  44.95  43.8053.92  18.0016:03:04May 0815 min RT 2¢

Recent Trades - Last 10 of 6282
Time ETExPriceChangeVolume
16:03:04Q44.840.07262
16:02:47Q44.840.0746
16:02:32Q44.840.07194
16:02:24Q44.840.0770
16:01:48Q44.840.07765
16:00:57Q44.840.078
16:00:55Q44.840.07130
16:00:53Q44.840.0727
16:00:51Q44.840.071,139
16:00:49Q44.840.072,759

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-08 07:00U:SWTXNews ReleaseSpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
2024-05-02 06:30U:SWTXNews ReleaseSpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
2024-04-24 13:32U:SWTXNews ReleaseSpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
2024-04-18 07:00U:SWTXNews ReleaseSpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
2024-03-04 06:30U:SWTXNews ReleaseSpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
2024-02-29 08:30U:SWTXNews ReleaseSpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
2024-02-27 06:30U:SWTXNews ReleaseSpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
2024-02-22 07:00U:SWTXNews ReleaseSpringWorks Therapeutics to Present at Upcoming Investor Conferences
2024-01-31 07:01U:SWTXNews ReleaseSpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
2024-01-08 06:31U:SWTXNews ReleaseSpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-21 07:00U:SWTXNews ReleaseSpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-08 16:05U:SWTXNews ReleaseSpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters ¢ € ™ Option to Purchase Additional Shares
2023-12-05 00:32U:SWTXNews ReleaseSpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
2023-12-04 16:13U:SWTXNews ReleaseSpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
2023-11-29 07:00U:SWTXNews ReleaseSpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
2023-11-27 18:04U:SWTXNews ReleaseSpringWorks Therapeutics Announces FDA Approval of OGSIVEO ¢ „ ¢ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
2023-11-16 06:30U:SWTXNews ReleaseSpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN
2023-11-02 06:30U:SWTXNews ReleaseSpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
2023-11-01 06:30U:SWTXNews ReleaseSpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting
2023-09-11 06:30U:SWTXNews ReleaseSpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer